Silence Therapeutics wants to put the kibosh on disease-causing genes. The company, formerly known as SR Pharma, is working in the field of RNA interference (RNAi), a cutting-edge approach to treating disease that involves interfering with, or silencing, targeted genes associated with disease. Its AtuPLEX drug delivery system is designed to work specifically with RNA molecules. Silence Therapeutics acquired fellow RNAi research company Intradigm in 2010, greatly expanding its RNAi program capabilities, which it hopes will make it a more attractive partner to bigger pharmaceutical companies looking to develop products based on that science.

Martek Biosciences Corporation was founded in 1985 and is headquartered in Columbia, Maryland. Martek Biosciences Corporation engages in the innovation and development of nutritional products from microbial sources, including algae, fungi, and other microbes worldwide. Its products include life'sDHA, a vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid) for use in infant formula, pregnancy and nursing products, foods and beverages, dietary supplements, and animal feeds; and life'sARA, a vegetarian source of the omega-6 fatty acid ARA (arachidonic acid) for use in infant formula. The company also provides contract manufacturing services for the production of enzymes, specialty chemicals, vitamins, and agricultural specialty products. It sells oils containing fatty acids under the names of life'sDHA, DHASCO, Neuromins, ARASCO, and life'sARA. The company markets its nutritional oils primarily to the infant formula, pregnancy and nursing, food and beverage, dietary supplement, and animal feed markets.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Antisoma plc company was founded in 1988. Antisoma is anti-cancer. The drug development firm scouts academic or cancer research institutions for promising new oncology drug candidates and snaps them up. Once the drugs are in its pipeline, Antisoma conducts preclinical and clinical trials. The company's leading candidates in clinical trials include possible treatments for lung cancer, acute myeloid leukemia, and breast cancer. Its 2008 acquisition of Xanthus Pharmaceuticals brought along more candidates, and helped Antisoma expand in the US. Antisoma also partners with larger drug makers and research groups, including Novartis, to develop and commercialize products.

Noven Pharmaceuticals, Inc. company develops drugs using its transdermal drug delivery system, which administers medication through a patch attached to the skin. Noven's patches include such female hormone replacement therapy products as Vivelle-Dot and CombiPatch, ADHD drug Daytrana (marketed by Shire), and a transmucosal lidocaine patch used for dental procedures. The company also produces and markets three psychiatric drugs. In 2009 Noven was acquired by Japanese drug-maker Hisamitsu Pharmaceutical for some $430 million.

Omega Diagnostics Group PLC is a United Kingdom-based holding company. The Company, along with its subsidiaries, is principally engaged in the manufacture, development and distribution of medical diagnostic products. The Company sells a range of products, primarily in the immunoassay, in-vitro diagnostics (IVD) market, through a distribution network in over 100 countries. The Company operates in a niche market in supplying tests for specific infectious diseases, autoimmune disease and food tolerance. The Company subsidiaries include Investment in Omega Diagnostics Limited, Investment in Genesis Diagnostics Limited, Investment in Cambridge Nutritional Sciences Limited, Investment in Bealaw (692) Limited and Investment in Bealaw (693) Limited.

AVAX Technologies company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate M-Vax is intended as a post-surgical treatment for late-stage melanoma, but the company is also developing vaccine candidates to fight ovarian cancer (O-Vax) and non-small cell lung cancer (L-Vax). The company also offers contract manufacturing services to other biotech and pharmaceutical companies.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Roche Scientific Company (India) is the Indian arm of Roche. Roche's products and services address the needs for prevention, diagnosis, and treatment of disease, and Roche Scientific Company (India) keeps the Indian product pipeline moving smoothly. The company, along with Roche Diagnostics (India), ensures Roche's products and services comply with Indian regulations including registration of new products, control of clinical trials, and monitoring of guidelines set by the International Federation of Pharmaceutical Manufacturers Association (IFPMA). The company also sponors research and development projects for new bulk drugs in India and disseminates product information via medical education programs.

TRANSGENE S.A. company was founded in 1979 and is based in Strasbourg, France. Transgene S.A. is a subsidiary of Merieux Alliance. Transgene S.A., a biopharmaceutical company, engages in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. The company’s products primarily include TG 4001/R3484, an immunotherapy targeting anti-infectious for human papilloma virus-associated pathologies, which completed Phase IIa trials; TG 4010, a cancer vaccine primarily for non small cell lung cancer, which is in Phase IIb trials; TG 1042, an immune enhancement gene therapy for cutaneous B-cell lymphoma, which is in Phase II trials; TG 4040, an anti-infectious therapeutic vaccine for chronic hepatitis C infection, which is in Phase I trials; and TG 4023, a preclinical suicide gene candidate for the treatment of 5-FU-sensitive tumors. It also offers a package of services relating to molecular biology, development, and biomanufacturing that include design and construction of new vaccines; development and/or adaptation of production process; development and/or adaptation of quality control assays; production and control of starting material for pharmaceutical and clinical development; and manufacturing material for clinical trials. Transgene S.A. has collaboration agreements with Roche, Association Francaise contre les Myopathies, and MIRUS; manufacturing and subcontracting agreements with International AIDS Vaccine Initiative, Innogenetics, Agence Nationale de Recherche contre le SIDA, Institut National de la Sante et de la Recherche Medicale, and EUROVACC; and licensing agreements with Merck, Imperial Cancer Research Technology, Ajinomoto, Aventis, and Cayla.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.